Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics
| Autor: | Ludger Hargarter, Pierre Cherubin, Andreas Schreiner, G. Corrivetti, Pierre-Michel Llorca, Paul Bergmans, Sofia Keim, B. Cosar, A. Petralia |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty non acute paliperidone palmitato schizophrenia paliperidone palmitate Pharmacology Severity of Illness Index Extrapyramidal symptoms Internal medicine Outcome Assessment Health Care Severity of illness Non-acute medicine Humans Pharmacology (medical) Prospective Studies Adverse effect Paliperidone Palmitate Risperidone Positive and Negative Syndrome Scale switching business.industry Middle Aged medicine.disease Original Papers 3. Good health injectable antipsychotic Psychiatry and Mental health Tolerability Schizophrenia Delayed-Action Preparations Female medicine.symptom business Antipsychotic Agents medicine.drug |
| Zdroj: | Journal of Psychopharmacology (Oxford, England) |
| ISSN: | 1461-7285 0269-8811 |
| DOI: | 10.1177/0269881115586284 |
| Popis: | PALMFlexS, a prospective multicentre, open-label, 6-month, phase IIIb interventional study, explored tolerability, safety and treatment response in adults ( n = 231) with non-acute but symptomatic schizophrenia switching to flexibly dosed paliperidone palmitate (PP) after unsuccessful treatment with risperidone long-acting injectable therapy (RLAT) or conventional depot antipsychotics (APs). Treatment response was measured by change in Positive and Negative Syndrome Scale (PANSS) total score from baseline (BL) to last-observation-carried-forward (LOCF) endpoint (EP). Safety and tolerability assessments included Extrapyramidal Symptom Rating Scale (ESRS) total score and treatment-emergent adverse events. Significant reductions in mean PANSS total score were observed for all groups (−7.5 to −10.6; p ⩽ 0.01 [BL to LOCF EP]). After switching to PP, more than 50% of all patients achieved ⩾20% and one-third of RLAT-treated patients even achieved ⩾50% improvement in PANSS total score. Across groups, there were significant improvements ( p < 0.05) in symptom severity as measured by Clinical Global Impression-Severity (CGI-S; trend for improvement with RLAT; p = 0.0568), subjective well-being, medication satisfaction, and patient functioning with PP. PP was generally well tolerated. Clinically relevant benefits were observed in non-acute patients with schizophrenia switched from RLAT or conventional depot APs to PP. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|